IKBKG antibody (N-Term)
-
- Target See all IKBKG Antibodies
- IKBKG (Inhibitor of kappa Light Polypeptide Gene Enhancer in B-Cells, Kinase gamma (IKBKG))
-
Binding Specificity
- N-Term
-
Reactivity
- Human, Mouse, Rat, Rabbit, Cow, Dog, Guinea Pig, Horse, Pig
-
Host
- Rabbit
-
Clonality
- Polyclonal
-
Conjugate
- This IKBKG antibody is un-conjugated
-
Application
- Western Blotting (WB)
- Sequence
- MNRHLWKSQL CEMVQPSGGP AADQDVLGEE SPLGKPAMLH LPSEQGAPET
- Predicted Reactivity
- Cow: 79%, Dog: 93%, Guinea Pig: 85%, Horse: 93%, Human: 100%, Mouse: 86%, Pig: 93%, Rabbit: 86%, Rat: 86%
- Characteristics
- This is a rabbit polyclonal antibody against IKBKG. It was validated on Western Blot using a cell lysate as a positive control.
- Purification
- Affinity Purified
- Immunogen
- The immunogen is a synthetic peptide directed towards the N terminal region of human IKBKG
- Top Product
- Discover our top product IKBKG Primary Antibody
-
-
- Application Notes
- Optimal working dilutions should be determined experimentally by the investigator.
- Comment
-
Antigen size: 419 AA
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- Lot specific
- Buffer
- Liquid. Purified antibody supplied in 1x PBS buffer with 0.09 % (w/v) sodium azide and 2 % sucrose.
- Preservative
- Sodium azide
- Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Handling Advice
- Avoid repeated freeze-thaw cycles.
- Storage
- -20 °C
- Storage Comment
- For short term use, store at 2-8°C up to 1 week. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.
-
- Target
- IKBKG (Inhibitor of kappa Light Polypeptide Gene Enhancer in B-Cells, Kinase gamma (IKBKG))
- Alternative Name
- IKBKG (IKBKG Products)
- Synonyms
- AMCBX1 antibody, FIP-3 antibody, FIP3 antibody, Fip3p antibody, IKK-gamma antibody, IP antibody, IP1 antibody, IP2 antibody, IPD2 antibody, NEMO antibody, ZC2HC9 antibody, 1110037D23Rik antibody, AI848108 antibody, AI851264 antibody, AW124339 antibody, IKK[g] antibody, Nemo antibody, nemo antibody, fj33c07 antibody, wu:fj33c07 antibody, zgc:113492 antibody, MGC97885 antibody, IKBKG antibody, IKBKG_1 antibody, IKBKG_2 antibody, CG16910 antibody, DmIKK-gamma antibody, DmIKKgamma antibody, Dmel\\CG16910 antibody, Dmikkgamma antibody, IKK antibody, IKK[[gamma]] antibody, IKKg antibody, IKKgamma antibody, KEY antibody, Kenny antibody, Key antibody, dIKK antibody, dIKK-gamma antibody, dmIKKgamma antibody, inhibitor of nuclear factor kappa B kinase subunit gamma antibody, inhibitor of kappaB kinase gamma antibody, inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma antibody, inhibitor of nuclear factor kappa B kinase subunit gamma L homeolog antibody, kenny antibody, IKBKG antibody, Ikbkg antibody, ikbkg antibody, ikbkg.L antibody, IKBKG_1 antibody, key antibody
- Background
-
IKBKG is the regulatory subunit of the IKK core complex which phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. IKBKG also considered to be a mediator for TAX activation of NF-kappa-B. IKBKG could be implicated in NF-kappa-B-mediated protection from cytokine toxicity.Familial incontinentia pigmenti (IP) is a genodermatosis that segregates as an X-linked dominant disorder and is usually lethal prenatally in males (The International Incontinentia Pigmenti Consortium, 2000 [PubMed 10839543]). In affected females it causes highly variable abnormalities of the skin, hair, nails, teeth, eyes, and central nervous system. The prominent skin signs occur in 4 classic cutaneous stages: perinatal inflammatory vesicles, verrucous patches, a distinctive pattern of hyperpigmentation, and dermal scarring. Cells expressing the mutated X chromosome are eliminated selectively around the time of birth, so females with IP exhibit extremely skewed X-inactivation. Familial incontinentia pigmenti is caused by mutations in the NEMO gene and is here referred to as IP2, or 'classical' incontinentia pigmenti. Sporadic incontinentia pigmenti, the so-called IP1, which maps to Xp11, is categorized as hypomelanosis of Ito (MIM 300337).[supplied by OMIM]. Sequence Note: removed 1 base from the 5' end that did not align to the reference genome assembly. Publication Note: This RefSeq record includes a subset of the publications that are available for this gene. Please see the Entrez Gene record to access additional publications. PRIMARYREFSEQ_SPAN PRIMARY_IDENTIFIER PRIMARY_SPAN COMP 1-2120 AF261086.1 2-2121
Alias Symbols: AMCBX1, FIP-3, FIP3, Fip3p, IKK-gamma, IP, IP1, IP2, IPD2, NEMO
Protein Interaction Partner: CHUK, IKBKB, ATM, PIAS4, MALT1, TRIM13, BCL10, SUMO1, UBC, TRAF6, MTOR, RPTOR, RELA, NFKBIA, IKBKG, ARHGDIA, RHOA, CDC37, SRC, FYN, FKBP5, FGR, PPP4C, PPP2R1B, LYN, NMRAL1, USP7, ZC3H12A, IRAK1, USP10, RIPK1, SQSTM1, RNF31, PPP1CC, HDLBP, PPFIA1, PSMB8, K
Protein Size: 419 - Molecular Weight
- 48 kDa
- Gene ID
- 8517
- NCBI Accession
- NM_003639, NP_003630
- UniProt
- Q9Y6K9
- Pathways
- NF-kappaB Signaling, RTK Signaling, TCR Signaling, TLR Signaling, Fc-epsilon Receptor Signaling Pathway, Activation of Innate immune Response, M Phase, Production of Molecular Mediator of Immune Response, Hepatitis C, Protein targeting to Nucleus, Toll-Like Receptors Cascades, BCR Signaling, Ubiquitin Proteasome Pathway, S100 Proteins
-